TLRY Tilray Brands, Inc.

Trulieve Cannabis falls after the Drug Enforcement Administration pauses pending rescheduling proceedings for a case that could federally recognize cannabis for medical use.

The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $4.02, representing a -2.66% change from its previous close.

The cannabis company is set to report its earnings early next month.

There's a reason why shares keep tumbling, despite signs of a turnaround.

Tilray Brands, Inc. (TLRY) concluded the recent trading session at $4.08, signifying a +2.26% move from its prior day's close.

The cannabis stock has been struggling badly this year, but there could be a catalyst up ahead.

The Scottish firm, which is now owned by Tilray Brands, has said there will be ‘a little less allegation’ and ‘no more cunning stunts’ in adverts.

Squatters took over several abandoned Brewdog pubs after the company collapsed, administrators said.

The company’s brand was snapped up by a US investor earlier this year.

The cannabis stock has moved quickly in the past when there's been talk of marijuana reform.

The Tilray bull case is getting stronger without U.S. legalization.

Tilray Brands, Inc. (TLRY) closed at $4.14 in the latest trading session, marking a +2.99% move from the prior day.

Tilray Brands has moved beyond marijuana, turning itself into a diversified brand manager.

Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.3, denoting a -4.44% move from the preceding trading day.

Don't expect a rebound anytime soon.

The Canadian cannabis companies are both seeing strong growth, but one is a better buy right now.

Tilray Brands, Inc. (TLRY) concluded the recent trading session at $4.5, signifying a -1.53% move from its prior day's close.

Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupiter Neurosciences Raised $2 Million as the Company Advances its Parkinson’s Drug Program Optimi Health Secured Discretionary Equity Facility as Psychedelic Drug Business Expands SciSparc […]

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.72, denoting a -2.48% move from the preceding trading day.

Recent results and legalization progress aren't the game changers you'd think they'd be for this cannabis stock.

Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.48, denoting a -4.07% move from the preceding trading day.

The cannabis stock has struggled despite Tilray achieving solid growth in its most recent fiscal year.

Tilray said it will move production from the Terrapin site in Georgia "to other breweries within our network".

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Why Tilray Brands stock is back on investors’ radar Tilray Brands (TLRY) has drawn fresh attention after launching its Mollo Lite Blackberry Lemon Seltzer 4-Pack, the first light THC multipack under the Mollo label in Canada’s cannabis beverage market. See our latest analysis for Tilray Brands. For investors watching Tilray Brands, the recent Mollo Lite launch comes after a mixed share price story, with a 1-day share price return of 3.04% and a 30-day share price return of 4.69%. This sits...

The company's true organic growth is difficult to gauge given its high dependency on acquisitions.

Tilray's distribution segment was the only one that generated double-digit growth in its most recent fiscal year.

Key Takeaways; Cannabis Sector Vireo Growth to Acquire Planet 13 in Landmark All-Stock Deal SNDL Completed Parallel Asset Acquisition, Expanding its U.S. Medical Cannabis Footprint Tilray Posted Record FY2026 Revenue as Cannabis Sales Rose and Losses Narrowed Key Takeaways; Psychedelic Sector Eli Lilly’s $3.8 Billion Deal to Acquire AtaiBeckley Signals a Major Push into Psychedelic-Inspired […]